Are you better off owning conventional mutual funds or exchange-traded-funds (ETFs) focusing on the same sector? I’ll tell you what you need to know, but leave the decision up to you.
Both mutual funds and ETFs track the returns of stocks or other securities in specified market sectors. But ETFs offer trading advantages. Unlike mutual funds, you can buy and sell ETFs just like stocks, and you pay the same commissions as you would for trading stocks. Most ETFs require no minimum investment, and there is no required holding period. ETFs can be traded at any time during the day, but mutual funds trade only once a day, after the market closes.
Although ETFs may be easier to trade, you’d think that mutual funds would generate better returns. Most are actively managed by professionals who can react to changing market conditions. By contrast, most ETFs either track fixed indexes, or indexes that can only be changed quarterly.
Crunching the Numbers
With that in mind, let’s see what the numbers show. We’ll start with China and India, which were last year’s hottest markets.
In China, an ETF called PowerShares China (CHNA) , racked up a 66% return, edging out managed mutual fund Matthews India Investor ($MINDX), which returned 64%.
In the U.S., biotechnology was the strongest category in 2014. There, First Trust Arca Biotech (FBT) , an ETF, gained 48% compared to 35% for the top mutual fund, Fidelity Select Biotechnology ($FBIOX).
Real estate investment trusts (REITs), a type of corporation limited to investing in commercial real estate, was another strong category last year. The top ETF focusing on REITs, iShares Residential Real Estate ($REZ), returned 35%, compared to 32% for the best mutual fund, Phocas Real Estate ($PHREX).
Obviously, last year’s numbers aren’t necessarily typical of long-term performance. Looking at three-year returns generally told a similar story, but the differences narrowed.
For instance, the top performing ETFs, Market Vectors Biotech (BBH) , up 45%, and First Trust Arca Biotech (FBT) , up 44%, narrowly beat the top funds, Fidelity Select Biotechnology ($FBIOX), up 44% and Rydex Biotechnology ($RYOAX), up 39% on average, annually.
After biotechs, pharmaceutical makers were the strongest category over the past three years. There, mutual fund T. Rowe Price Health Sciences ($PRHSX) was up 37%, edging out the top ETF, PowerShares Dynamic Pharmaceuticals (PJP) , which returned 36%.
Transportation stocks, e.g. railroads and airlines, also outperformed over the past three years. Looking at that sector, the SPDR S&P Transportation ETF (XTN) was up 29%, outperforming the best mutual fund, Fidelity Select Transportation ($FSRFX), which gained 26%.
Now that you have the numbers, you can draw your own informed conclusions.
For these comparisons, I considered only no-load mutual funds currently open to individual investors and unleveraged ETFs, meaning that they do not attempt to double or triple their sector’s returns.
For tips and information on the best utilities and dividend stocks from Harry Domash, please check out Dividend Detective.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer